Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fortelyzin vs Surgery in Acute Limb Ischemia
NCT05372718Phase 3Completed
- Sponsor
- SuperGen, Inc.
- Start
- Dec 2022
- Primary completion
- Sep 2026
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of staphylokinase in acute limb ischemia (ALI) (2 arms), sponsored by SuperGen, Inc. Primary endpoint: Number of patients without amputations at 30 days. Started Dec 2022; status: completed.
02
Drugs
staphylokinase
03
Conditions
acute limb ischemia (ALI)
Beyond the preview
Go deeper on NCT05372718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372718.